Approximately 5-10% of breast cancers are hereditary. Among hereditary syndromes, Hereditary Breast and Ovarian Cancer Syndrome (HBOC) and Li-Fraumeni Syndrome (LFS) have received the most attention. HBOC is due to mutations in the BRCA1 and BRCA2 genes and is characterized by breast adenocarcinoma and/or epithelial ovarian carcinoma. LFS is associated with germline mutations in TP53; the most frequent cancer types associated with this syndrome are sarcoma, breast cancer, leukemia, brain tumors and adrenocortical carcinomas. Other cancers related to LFS are found at lower frequencies. In Brazil, especially in the southern part of the country, a specific mutation in the TP53 gene, TP53 p.R337H, occurs at a high frequency in childhood adrenocortical tumors. It has been proposed that this mutation increases breast cancer risk in southern Brazilian women.
Methods
We carried out a case-control study to determine the prevalence of the TP53 p.R337H mutation in 28 female cancer patients attended at the Cancer Genetic Counseling Service of the General Hospital of the University of São Paulo Medical School of Ribeirão Preto who fulfilled Hereditary Breast and Ovary Cancer Syndrome genetic test criteria compared to healthy woman (controls). TP53 p.R337H mutation status was determined using the High Resolution Melting (HRM) method, followed by DNA sequencing. Fisher’s test was used to compare the prevalence of TP53 p.R337H in the patient and control groups.
Results
Two of the breast cancer cases (7.1%) and none of the controls carried the TP53 p.R337H mutation. At the time of the investigation, both cases fulfilled testing criteria for Hereditary Breast and Ovary Cancer Syndrome but not Li-Fraumeni or Li-Fraumeni-like Syndrome, based on genetic testing criteria of NCCN Clinical Practice Guidelines in Oncology (v.1.2010).
Conclusions
We suggest that genetic screening of Brazilian breast cancer patients who fulfill Hereditary Breast and Ovary Cancer Syndrome criteria and have a family history that includes other tumors of the LFS/LFL spectrum be tested for the TP53 p.R337H mutation.
The online version of this article (doi:10.1186/1897-4287-12-8) contains supplementary material, which is available to authorized users.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
WASJ conceived the study. NMC participated in the study design, conducted the mutation analysis, statistical analysis and manuscript preparation. VEFF participated in the study design, acquisition of data, statistical analysis and revised the manuscript critically. All authors read and approved the final manuscript.
Abkürzungen
BRCA1
Breast cancer susceptibility gene 1
BRCA2
Breast cancer susceptibility gene 2
HBOC
Hereditary breast and ovary cancer syndrome
HCFMRP-USP
General Hospital of the University of São Paulo Medical School of Ribeirão Preto
HRM
High resolution melting
CIs
Confidence intervals
LFL
Li-Fraumeni like
LFS
Li-Fraumeni syndrome
NCCN
National Comprehensive Cancer Network
OR
Odds ratio
PCR
Polymerase chain reaction
WHO
World Health Organization.
Background
The World Health Organization (WHO) estimates that over one million women are affected annually by breast cancer [1]. In Brazil, breast cancer is the most prevalent cause of death due to cancer among women from 40 to 69 years old [2]. About 5-10% of breast cancers are hereditary, and approximately 30% of young women who develop this type of cancer have a predisposition to disease [3‐6]. Two major hereditary cancer predisposition syndromes are related to hereditary breast cancer phenotype: Hereditary Breast and Ovarian Cancer Syndrome (HBOC) and Li-Fraumeni Syndrome (LFS). HBOC is due to mutations in the BRCA1 and BRCA2 genes; it is characterized by ductal or lobular breast adenocarcinoma and epithelial ovarian carcinoma [7].
In 1990, LFS was found to be associated with germline mutations in TP53[8]. Pathogenic mutation carriers for this gene have a cumulative risk of up to 90% for the development of a cancer spectrum, which is usually diagnosed before the age of 45. The most frequent cancer types include sarcoma, breast cancer, brain tumors, leukemia and adrenocortical carcinomas. Other cancers are observed at a lower frequency, including lymphomas, gastric cancer and melanoma [9, 10]. Families that do not have the classic phenotype of this syndrome are called Li-Fraumeni like (LFL) or Li-Fraumeni variant (Table 1) [11‐13]. The NCCN Clinical Practice Guidelines in Oncology v.4.2013 take into account only classic LFS and Chompret criteria for LFS/LFL genetic testing [14].
Proband diagnosed with sarcoma before age 45, and a FDR with cancer before age 45, and another first- or second-degree relative with any cancer diagnosed under age 45 or with sarcoma at any age
Proband with any childhood cancer or sarcoma, brain tumor, or adrenocortical carcinoma diagnosed under 45 years, and a FDR or SDR with a typical Li-Fraumeni syndome-related cancer (sarcoma, breast cancer, brain tumor, leukemia, or adrenocortical carcinoma) diagnosed at any age and an FDR or SDR in the same genetic lineage with any cancer diagnosed under the age of 60
Two different tumors that are part of the extended Li-Fraumeni syndome in FDR or SDR at any age (sarcoma, breast cancer, brain tumor, leukemia, adrenocortical tumor, melanoma, prostate cancer, and pancreatic cancer)
I—Proband diagnosed with tumor belonging to Li-Fraumeni syndome spectrum (soft tissue sarcoma, osteosarcoma, brain tumor, premenopausal breast cancer, adrenocortical carcinoma, leukemia, lung bronchoalveolar cancer) before age 46 and at least one first- or second degree relative with Li-Fraumeni syndrome cancer (except breast cancer if the proband has breast cancer) under the age of 56 years or with multiple tumors at any age
II—Proband with multiple primary tumors (except multiple breast), two of which belong to Li-Fraumeni syndome tumor spectrum and the first of which occurred before age 46
III—Proband with adrenocortical carcinoma or choroid plexus tumor at any age, irrespective of family history
Given the similar mutation rates of the BRCA1, BRCA2 and TP53 genes, Lee et al. [15] proposed that women who developed breast cancer before 30 years of age should undergo genetic testing for all three genes simultaneously. Custodio et al. (2013) estimated an overall frequency of 0.2-0.3% for TP53 p.R337H in a southern Brazil state [16]. This mutation has been identified in >90% of Brazilian patients with childhood adrenocortical carcinoma, a rare but remarkably frequent tumor in southeastern and southern Brazil [16]. It also has been proposed that this mutation increases breast cancer risk in women, especially in southern Brazil [17‐19]. The frequency of TP53 p.R337H in women with breast cancer has been reported as 2.4% [18], while in healthy women it is only 0.3% [20].
Given this potential association with breast cancer and the high frequency of TP53 p.R337H in southern Brazil, we conducted a case-control study to compare TP53 p.R337H mutation prevalence in healthy controls with that in female breast cancer patients in Ribeirão Preto, Sao Paulo state, located in southeast Brazil. The affected women fulfilled HBOC genetic test criteria, according to NCCN Clinical Practice Guidelines in Oncology v.1.2010 [21].
Methods
Subjects
This study was approved by the Ethics Committee of the University of Sao Paulo Medical School of Ribeirão Preto, SP, Brazil; informed consent was obtained from participants. We analyzed 28 DNA samples of unrelated women diagnosed with breast cancer that fulfilled the criteria for HBOC genetic testing according to NCCN Clinical Practice Guidelines in Oncology v.1.2010 [21] (Table 2). All patients were enrolled in the Cancer Genetic Counseling Service of the General Hospital of the University of São Paulo Medical School of Ribeirão Preto (HCFMRP-USP).
Table 2
Patient criteria for genetic testing according to NCCN clinical practice guidelines in oncology v.1.2010 [21] for HBOC
Patient 1
Patient 2
Criteria
X
Personal history of breast cancer ≤ 45 years
Personal history of two primary breast cancers, the first being diagnosed before 50 years of age
Personal history of breast cancer with age at diagnosis < 50 years with limited family history
X
Personal history of breast cancer ≤ 50 years with ≥ 1 relative with breast cancer ≤ 50 years and/or ≥ 1 relative with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer at any age
Personal history of triple-negative breast cancer, with age at diagnosis < 60 years
X
Personal history of breast cancer at any age, with ≥ 2 relatives with breast cancer and/or epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer at any age
Personal history of breast cancer + Personal history of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
The control group was formed by 120 healthy women, age-matched to cases (Table 3), without family history of cancer, randomly selected among women attended at HCFMRP-USP and unrelated to the patients.
Table 3
Patient and control group clinical features
Features
Patient group
Control group
Number
28
120
Age (years)
41.75 (±10.25)
41.95 (±10.58)
Gender
F: 28 (100%)
F: 120 (100%)
F, Female.
Anzeige
Sample collection
Peripheral blood samples (10 mL) were collected into vacutainer tubes containing EDTA, while they were attended at the clinic. Genomic DNA was extracted using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA), following the manufacturer’s recommendations and stored at -20°C until genotyping analysis. The samples were collected from March 2009 to June 2010.
Genotype determination
High Resolution Melting (HRM)
The HRM method was used to detect the TP53 p.R337H mutation. The HRM primer sequences were as described by Bastien et al. [22]. Reactions were performed with a total volume of 20 uL (3.6 uL of MiliQ water, 1.2 mL of each primer at 5 pmol/uL, 10 uL of MeltDoctor HRMTM Master Mix (Applied Biosystems) and 4 uL of DNA at 5 ng/uL). The amplification parameters were: 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds and annealing temperature for 1 minute. For melting curve analysis, the parameters were: 95°C for 10 seconds, 60°C for 1 minute, 95°C for 15 seconds and 60°C for 15 seconds. The samples with different melting curves were sequenced to validate and characterize the mutation.
DNA sequencing
For TP53, the different melting curve fragments were sequenced in an automatic sequencer XL 3500 Genetic Analyzer (Applied Biosystems). The reaction consisted of 1 to 2 uL of amplified DNA, 2 uL of Big Dye Terminator v3.1 Cycle, 2 uL of 5X Sequencing Buffer (Applied Biosystems), 1 uL of primer and sufficient water to complete 10 uL. The amplification parameters of the sequencing reaction were: 95°C for 1 minute followed by 25 cycles of 95°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 minutes.
The complete coding sequence and exon-intron boundaries of BRCA1 and BRCA2 were analyzed in two TP53 p.R337H positive females. The sequences of the primers were those described by Leeneer et al. [23], and Keshavarzi et al. [24], respectively.
Statistical analyses
The TP53 p.R337H mutation frequency in breast cancer patients and controls was compared using Fisher’s exact test with GraphPad Prism 5 software to calculate odds ratios (OR), with confidence intervals (CIs) of 95%. A p-value of <0.05 was considered to be statistically significant. The TP53 p.R337H frequency in breast cancer patients was compared to the estimated Brazilian population frequency [16], which we assumed to be the true prevalence rate for the Brazilian population, using the one-sided exact test for binomial proportions.
Results
Twenty-eight women diagnosed with breast cancer were tested for TP53 mutations; two of them (7.1%) were found to carry a pathogenic mutation, heterozygous TP53 p.R337H (Figure 1). Both are negative for BRCA1 and BRCA2 pathogenic mutations. TP53 p.R337H is known to be more frequent in women with breast cancer, especially in families in southern Brazil suspected to have Li-Fraumeni Syndrome [17].
Figure 1
TP53p.R337H mutation detection. A) Melting curves for each specific genotype identified in exon 10 of the TP53 gene containing the TP53 p.R337H mutation; B) Sequencing results of a heterozygous TP53 p.R337H mutation sample (melting curve in blue) and a wild type sample (melting curves in green).
×
Patient 1 was diagnosed with parotid cancer at age 60 and bilateral breast cancer at age 61 in the left breast and age 62 in the right breast. Her brother had Central Nervous System cancer at age 58. Nevertheless, she did not meet the criteria for Li-Fraumeni Syndrome according to NCCN Guidelines v.1.2010 [21] and v.4.2013 [14], because the tumors related to the Li-Fraumeni Syndrome spectrum, in this case breast and prostate cancer, were diagnosed in third degree relatives (Figure 2). In the context of HBOC, she fulfilled the criteria of bilateral breast cancer personal history at any age, as two third-degree relatives were also diagnosed with breast cancer (Table 2).
Figure 2
Pedigree of patient 1, showing cancer history and theTP53p.R337H mutation. Arrow indicates the proband; present age or age at death is indicated below individuals. The cancer diagnosis age is indicated in brackets. wt = wild type.
×
Patient 2 was diagnosed with breast cancer at age 30. Her sister and her cousin were diagnosed with breast cancer at ages 42 and 35, respectively. Both had the same TP53 mutation; they were heterozygous for TP53 p.R337H. Additionally, her uncle was diagnosed with prostate cancer after he turned 60. Other tumors that are not part of the Li-Fraumeni Syndrome spectrum were diagnosed in second and third-degree relatives (Figure 3). There were two HBOC criteria for this patient: breast cancer personal history before 45 years old and family history of breast cancer before 50 years old; one first-degree relative and one third-degree relative were diagnosed with breast cancer before they were 50 (Table 2).
Figure 3
Pedigree of patient 2, showing cancer history and theTP53p.R337H mutation. Arrow indicates the proband; present age or age at death is indicated below individuals. The cancer diagnosis age is indicated in brackets. wt = wild type.
×
The HBOC criteria fulfilled for all 28 patients based on NCCN Guidelines v1.2010 [21] continued without change in v4.2013 [14].
Though both patients had a family history that included other tumors at the time of investigation, they did not fulfill the criteria for Li-Fraumeni Syndrome, according to NCCN Clinical Practice Guidelines in Oncology v.1.2010 [21]. However, the v.4.2013 [14] of these guidelines (Table 4) indicated that individuals with breast cancer by 35 years of age, not before 30 years of age as in previous version, and negative for BRCA1/2 fulfills LFS testing criteria. Consequently, according to the latest NCCN guidelines, patient 2 fulfills the criteria for LFS. In addition to the classic LFS [25] and Chompret [26] criteria, there are two more clinical criteria, called Birch [11] and Eeles [12]. Patient 1 just meets Eeles criteria for LFL, the less stringent one.
Table 4
Genetic testing criteria according to NCCN clinical practice guidelines in oncology v.4.2013 [14] for LFS
Criteria
Description
Familial TP53 mutation
Individual from a family with a known TP53 mutation
Early-onset breast cancer
Personal history of breast cancer ≤ 35 years of age with a negative BRCA1/2 test
Classic LFS criteria
Personal history of sarcoma < 45 years + 1 first-degree relative with cancer diagnosed at age <45 years + 1 first- or second-degree relative in the same lineage with cancer diagnosed at age < 45 years or sarcoma at any age
Chompret criteria
Personal history of a tumor of the LFS spectrum (eg. soft tissue sarcoma, osteosarcoma, brain tumor, breast cancer, adrenocortical carcinoma, leukemia, lung bronchoalveolar cancer) before 46 years of age + at least one first- or second-degree relative with any of the aforementioned cancers (other than breast cancer if the proband has breast cancer) before the age of 56 years or with multiple primaries at any age
Personal history of multiple tumors (except multiple breast tumors), two of which belong to the LFS tumor spectrum, with the initial cancer occurring before the age of 46 years
Personal history of adrenocortical carcinoma or choroid plexus carcinoma at any age of onset, regardless of family history
LFS, Li-Fraumeni Syndrome.
In comparison with the two of 28 HBOC breast cancer women patients who had the TP53 p.R337H mutation, none of the 120 healthy women without family history of cancer had this mutation. We found a significant association of TP53 p.R337H mutation with breast cancer (p = 0.0347; Table 5). Comparing our results with the overall frequency of TP53 p.R337H in southern Brazil, assumed by Custodio et al. (2013) to be in the range of 0.2–0.3% [16], we found that the TP53 p.R337H mutation frequency was significantly higher among breast cancer women with HBOC than in the general Brazilian population (p = 0.001 and 0.003 in comparison to 0.2 and 0.3%, respectively; one-sided exact binomial test).
Table 5
TP53 P.R337H frequency in breast cancer patients with HBOC criteria and control groups
TP53 P.R337H
Control (n = 120)
Breast cancer (n = 28)
P
OR 95% CI
Arg/Arg
120 (100%)
26 (92.9%)
0.0347
0.0439 (0.0020 to 0.9438)
Arg/His
0
2 (7.1%)
Anzeige
Discussion
Based on our study, we suggest that TP53 p.R337H mutation prevalence in breast cancer patients suspected of HBOC in Ribeirão Preto, São Paulo, Brazil is high (7.1%). This result falls within the range of that found in previous studies conducted in southern Brazil (2.4-13%) [17, 18]. However, the study by Achatz et al. is based on LFS/LFL families with tumors other than breast cancer.
This mutation is responsible for exchanging an arginine for a histidine (CGC to CAC) at codon 337, located at an oligomerization domain of p53 protein. It has been primarily associated with adrenocortical tumors in children [27, 28].
Contact of alpha-helices of two adjacent monomers through a hydrogen bond is critical to oligomer stability and hence for p53 binding to DNA. Because histidine pKa is lower than arginine pKa, increased pH conditions (pH 8.3) cause histidine deprotonation, making it incapable of forming a hydrogen bond, consequently preventing protein binding to DNA [27, 29]. However, the pathogenicity of TP53 p.R337H is still questionable due to the low number of functional studies.
Achatz et al. (2007) [17] screened for the TP53 p.R337H mutation in 45 Brazilian subjects from unrelated families with cancer histories suggestive of LFS. They found the mutation in six cases (13%). Interestingly, the most common tumor type in these families was breast cancer (30.4%).
Anzeige
Assumpção et al. (2008) [18] estimated the prevalence of this mutation in 123 breast cancer cases and 223 age-matched controls. Three of the cases (2.4%) and none of the controls were carriers of the TP53 p.R337H mutation (P = 0.04). All three cases were relatively young at diagnosis (range 19-44 years old), and two of the three cases had a family history suggestive of LFS.
The role of the TP53 p.R337H mutation in breast carcinogenesis is still unclear. Achatz et al. (2007) found that, in an invasive ductal breast adenocarcinoma sample, the TP53 p.R337H mutation was homozygous in tumor tissue and heterozygous in peripheral blood, suggesting a role in tumor development. However, Assumpção et al. (2008) found the mutant TP53 p.R337H allele to be absent in the three breast tumors examined.
Gomes et al. (2012) [30] evaluated TP53 p.R337H mutation frequency in 390 unselected breast cases and 324 controls from Rio de Janeiro state. Two of the breast cancer cases (0.5%) and none of the controls carried the mutation. Both cases had an early age at diagnosis (<40 years old) and a family history including breast and other cancer types.
Our study shows that TP53 p.R337H is found in women who fulfill HBOC genetic testing criteria but not the LFS criteria, according to NCCN Clinical Practice Guidelines in Oncology v.1.2010 [21]. The change made in v.4.2013 [14] of these guidelines led us to include patient 2 in LFS genetic testing criteria, but not patient 1. This patient potentially fulfills the Eeles criteria, which is not included in NCCN testing criteria. This fact, associated with the apparently high frequency of TP53 p.R337H mutation in the population that we analyzed, reinforces the necessity of adjusting genetic testing criteria for hereditary syndromes according to local populations characteristics.
Anzeige
It has been suggested that TP53 genetic testing should be considered for women diagnosed with breast cancer under age 30 after they have previously tested negative for mutations in BRCA1 and BRCA2[31]. However, given similar mutation rates in early breast cancer, Lee et al. (2012) [15] proposed that these women should undergo genetic testing for mutations in all three genes at the same time. Taking into account the high frequency of the TP53 p.R337H mutation in Brazilian women with breast cancer [17, 18, 20, 30], and given that the TP53 p.R337H genetic test (single nucleotide change at codon 337) is easy, fast and inexpensive, we suggest that the TP53 p.R337H mutation screening should not be restricted to early breast cancer patients, but to all Brazilian breast cancer patients with a family history that includes other LFS/LFL tumors.
One important limitation of our study is the relatively small number of subjects. Nevertheless, the association of TP53 p.R337H mutation with breast cancer that we found is enough to lead us to suggest that TP53 p.R337H mutation screening should be conducted at the same time as BRCA testing and not necessarily only after patients have previously tested negative for BRCA gene mutations. This could speed up diagnosis of breast cancer and help optimize genetic counseling procedures.
Conclusions
Our study shows that TP53 p.R337H mutation prevalence in breast cancer patients suspected of Hereditary Breast and Ovary Cancer Syndrome in Ribeirão Preto, São Paulo, Brazil is high (7.1%) and could play an important role in predisposition to breast cancer in this population. However, there is currently no robust evidence for a role of this mutation in breast carcinogenesis.
We propose that TP53 p.R337H mutation screening be conducted in Brazilian women who have been diagnosed with breast cancer at any age, who fulfill Hereditary Breast and Ovary Cancer Syndrome genetic testing criteria and have a family history that includes other tumors of the LFS/LFL spectrum.
Acknowledgements
We thank Adriana Aparecida Marques and Cristiane Ayres Ferreira for technical support. This work was supported by grant 1998/14247-6 of the São Paulo Research Foundation (FAPESP), CNPQ grant 573754/2008-0, and CAPES. The authors also thank Sandra Navarro Bresciani for preparing the figures.
Open Access
This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License (
https://creativecommons.org/licenses/by/2.0
), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (
https://creativecommons.org/publicdomain/zero/1.0/
) applies to the data made available in this article, unless otherwise stated.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
WASJ conceived the study. NMC participated in the study design, conducted the mutation analysis, statistical analysis and manuscript preparation. VEFF participated in the study design, acquisition of data, statistical analysis and revised the manuscript critically. All authors read and approved the final manuscript.
